---
title: "Valiant's shareholder LUYIN INVEST has cumulatively increased its holdings by 7.7787 million shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234392313.md"
description: "According to the Zhitong Finance APP, Valiant announced that its shareholder LUYIN INVEST increased its holdings of the company's shares by a total of 7.7787 million shares through self-owned funds and a special loan for stock increases via centralized bidding from March 18, 2025, to April 3, 2025"
datetime: "2025-04-03T10:39:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234392313.md)
  - [en](https://longbridge.com/en/news/234392313.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234392313.md)
generator: "portal-rs"
---

# Valiant's shareholder LUYIN INVEST has cumulatively increased its holdings by 7.7787 million shares

According to the Zhitong Finance APP, Valiant (002643.SZ) announced that its shareholder LUYIN INVEST will increase its holdings of the company's shares by a total of 7.7787 million shares through self-owned funds and special loans for stock increases via centralized bidding from March 18, 2025, to April 3, 2025

### Related Stocks

- [002643.CN](https://longbridge.com/en/quote/002643.CN.md)
- [600784.CN](https://longbridge.com/en/quote/600784.CN.md)

## Related News & Research

- [BYD launches Sealion 08 SUV, bolstering Ocean lineup's flagship push](https://longbridge.com/en/news/297765654.md)
- [Tencent opens WorkBuddy to third-party developers with 100+ partners](https://longbridge.com/en/news/297868451.md)
- [SOTL: Record revenue, margin expansion, and innovation drive robust growth and future optimism](https://longbridge.com/en/news/297615048.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)
- [Adamera Defines IP Anomaly with Minimum Width of 2.8km at Max Copper-Gold Target, South Hedley Project, BC, IP Program Resumes as Wildfire Risks Ease](https://longbridge.com/en/news/297778308.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**